Fig. 1: PROTAC improves antibodies internalization targeting oncogenic tyrosine kinase receptors. | Communications Biology

Fig. 1: PROTAC improves antibodies internalization targeting oncogenic tyrosine kinase receptors.

From: Proteolysis targeting chimera (PROTAC)-driven antibody internalization of oncogenic cell surface receptors

Fig. 1

Cellular internalization of labeled antibodies was evaluated by in vitro live-cell imaging, plotted as AUC of Red integrated intensity over percentage of cell confluence as (RCU × µM2/Well/%) in (a) breast cancer cell lines expressing HER2 (BT-474 and SKBR3) treated with PROTAC SJF1528 100 nM and Tmab at 4 µg/mL compared against DMSO and Tmab at 4 µg/mL control condition. b Lung (A549) and pancreatic (BxPC-3) cancer cells expressing EGFR treated with PROTAC SJF1528 100 nM and Cmab at 4 µg/mL and 2 µg/mL, respectively. c MET cell models treated with PROTAC 48-284 500 nM and anti-MET antibody at 4 µg/mL for HCC827 GR6 (Lung) and HEK 293T treated with PROTAC 48-284 500 nM and anti-MET antibody at 4 µg/mL. Data shown here are representative experiments, every condition has been done in triplicate and lines and error bars represent the medians and SEM Individual data points are available in the Supplementary Data file. Statistical significance was evaluated with GraphPad Prism 10 by unpaired t-test and two-tailed p value. ***P < 0.001; ****P < 0.0001.

Back to article page